1. Nashed A, Zhang S, Chiang CW, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH and Li L. Comparative Assessment of Manual Chart Review and ICD Claims Data in Evaluating Immunotherapy-Related Adverse Events. Cancer Immunology, Immunotherapy.2021 doi:10.1007/s00262-021-02880-0. Online ahead of print. PMID:33625533
2. Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino E, Kendra K, Spakowicz D, Otterson G, Presley C, Owen D. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. Journal of Cancer Research and Clinical Oncology.2022. doi:10.1007/s00432-022-04340-3. Online ahead of print. PMID:36070148
3. Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan L, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Cross CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Journal of Clinical Lung Cancer.2022. Doi:10.1016/j.cllc.2021.12.010. Online ahead of print. PMID: PMC9149057
1. Nashed A, Zhang S, Chiang CW, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH and Li L. Comparative Assessment of Manual Chart Review and ICD Claims Data in Evaluating Immunotherapy-Related Adverse Events. Cancer Immunology, Immunotherapy. 2021 doi: 10.1007/s00262-021-02880-0. Online ahead of print. PMID: 33625533
2. Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino E, Kendra K, Spakowicz D, Otterson G. Presley C, Owen D. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. Journal of Cancer Research and Clinical Oncology. 2022. Doi: 10.1007/s00432-022-04340-3. Online ahead of print. PMID: 36070148
3. Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan L, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Cross CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Journal of Clinical Lung Cancer. 2022. Doi: 10.1016/j.cllc.2021.12.010. Online ahead of print. PMID: PMC9149057
1. Lopez G, Folefac E, Pravin M, Jukich M, Collier K, Robins E, Coss C, Mace T, Li Z, Otterson GA, Stover D, Phelps M, Owen DH. A Pilot Study of Blood-Based Biomarkers for Response to Immune Checkpoint Inhibitors. Virtual presentation, Pelotonia Institute for Immuno-Oncology (PIIO) Second Annual Immuno-Oncology Symposium, Columbus, OH, November 2, 2020.
2. Lopez, G, Suhr, J. Gender Differences in the Relationship of Attention Deficit/Hyperactivity (ADHD) Symptoms to Alcohol Use/Misuse in Undergraduates. In-person presentation. Ohio University Student Expo, Athens OH, April 12, 2018
1. Prosek J, Owen D, Husain M, Wei L, Lopez G, Zhao S. Statin Use, Renal Cell Carcinoma, and Combination Immunotherapy Increase Risk of Checkpoiint Inhibitor-Induced Nephritis: A single-Center Database Study. Virtual poster presentation at the American Society of Nephrology Annual Meeting, Abstract PO2166. October 22nd 2020.
2. Wood C, Lopez G, Zhao L, Li M, Suryha N, Pael SH, Grogan M, Bertion EM, Shields PG, He K, Carbone DP, Otterson GA, Presley CJ, Pannecouk B, Kalemkaerian GP, Schnieder B, Gadgeeel SM, Ramnath N, Owen DH, Qin A. Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome. Virtual poster presentation, IASLC 2020 World Conference on Lung Cancer, Singapore, Worldwide Virtual Event, January 28-31, 2021.
3. Das P, Zhao S, Wei L, Miah A, Li M, Lopez G, Patel SH, Johns A, Gorgan M, Bertion EM, He K, Shields PG, Carbone CP, Otterson GA, Presley CJ, Owen DH. Bone metastases and overall survival in patients with metastatic non-small cell lung cancer treated with pembrolizumab. Virtual poster presentation, IASLC 2020 World Conference on Lung Cancer, Singapore, Worldwide Virtual Event, January 28-31, 2021.
4. Surya N, Li M, Zhao S, Patel SH, Lopez G, Johns A, Grogan M, Bertino EM, He K, Shields PG, Carbone DP, Otterson GA, Presley CJ, Owen DH. Prognostic value of Neutrophil to Lymphocyte ratio in NSCLC patients receiving first line Immune Checkpoint Inhibitor therapy. Virtual poster presentation, IASLC 2020 World Conference on Lung Cancer, Singapore, Worldwide Virtual Event, January 28-31, 2021.
5. Das P, Zhao S, Wei L, Miah A, Li M, Lopez G, Pate Sl, Johns A, Grogan M, Bertino E, He K, Shields P, Carbone D, Otterson G, Presley C, Owen D. Bone Modifying Agents and Skeletal Related Events in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Accepted for ASCO Virtual Poster presentation, May 2021
6. Husain M, Xu M, Patel S, Johns A, Grogan M, Li M, Lopez G, Miah A, Hoyd R, Liu Y, Muniak M, Haddad T, Tinoco G, Kendra K, Otterson G, Presley C, Spakowicz D, Owen D. Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: impact on survival across tumor types and prior therapy. Accepted ASCO Virtual Poster presentation. May 2021
Curriculum Committee Representative, Class of 2026
Clinical Central Representative, Class of 2026
Physical Medicine & Rehab club
Vice President, Sigma Sigma Phi Fraternity
Medical Mentoring Program